IGXT (Mcap $29 M) 1x Drug launched + 2x NDA filings in 1Q13 + Profitable in 2013 = 10 BAGGER EASILY !!!
THIS UNKNOWN GEM IS THE CHEAPEST STOCK WITH THE HIGHEST UPSIDE POTENTIAL IN THE BIOTECH SECTOR .PLEASE DO YOUR OWN DD AND REALIZE THE MEGA MONSTER POTENTIAL GLTA
Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by mid 2013 because of its very low burn-rate of $1.2 Mil a year !
2x New NDA filings for Migraine and Erectile Dysfunction indication in early 2013 .9x Drugs in their Mega Pipeline which will be all on Market within next 2-3 years !
IGXT has NO DEBT and the Market cap of only 29 M is more than RIDICULOUS for this GOLDMINE .
Market Cap : $ 29 M
Cash: $ 3 M ( Burn-rate only $1.2 M a year )
Price : 0.59 $
Shares Out : 50 M ( 26 M shares are held by Insiders + Institutions)
IntelGenx Submits New Drug Application for Anti-Migraine VersaFilm(TM)
Mar 27, 2013 6:05 AM EDT
IntelGenx Corp. (IGXT) a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.
The company had previously announced a successful a pre-NDA meeting with the FDA following the successful completion of a bioequivalency study demonstrating that its oral film product is bioequivalent with Maxalt MLT(R), a leading branded anti-migraine product manufactured by Merck & Co. According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.